Intravenous Oliceridine and Opioid-related Complications

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

December 21, 2023

Study Completion Date

January 10, 2024

Conditions
Major Surgery
Interventions
DRUG

Oliceridine

Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.

Trial Locations (3)

27157

Wake Forest Bapist Medical Center, Winston-Salem

44111

Cleveland Clinic Fairview Hospital, Cleveland

44195

Cleveland Clinic Main Campus, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT04979247 - Intravenous Oliceridine and Opioid-related Complications | Biotech Hunter | Biotech Hunter